Molecular Imaging of the Dopamine Transporter

Andrea Varrone and Christer Halldin

Centre for Psychiatry Research and Stockholm Brain Institute, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

The dopamine transporter (DAT) is a transmembrane protein responsible for reuptake of dopamine from the synaptic cleft and termination of dopaminergic transmission. Several radioligands are available for DAT imaging with SPECT and PET. This review summarizes the main SPECT and PET radioligands and the main applications of DAT imaging in neuropsychiatric disorders.

Key Words: Parkinson; DAT availability; substantia nigra

The neurotransmitter dopamine is one of the main monoamine transmitters in the brain and is involved in the regulation of important brain functions such as locomotor activity, reward, and cognition. The dopamine transporter (DAT) is a plasma membrane protein expressed exclusively in dopamine neurons, where it acts by rapidly clearing dopamine released into the extracellular space, thus regulating the amplitude and duration of dopamine signaling (*1*). In mammalian brain, the DAT protein is distributed mainly in the mesencephalic dopamine neurons of the substantia nigra pars compacta and of the ventral tegmental area and is particularly enriched in the striatum and nucleus accumbens.

Radioligands for In Vivo Imaging of DAT

Several SPECT and PET radioligands for DAT are available. SPECT radioligands such as ^{123}I-*N*-3-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (^{123}I-FP-CIT, also referred to as ^{123}I-β-CIT-FP, ^{123}I-ioflupane, and DaTSCAN [GE Healthcare]) and ^{123}I-2β-carbomethoxy-3β-(4-iodophenyl)tropane (^{123}I-β-CIT, also referred to as DOPASCAN [MAP Medical Techologies]) are commercially available. ^{123}I-FP-CIT is widely used in Europe, and its approved indications are differential diagnosis between essential tremor and degenerative parkinsonism (Fig. 1) and differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer disease (AD) (*2*). ^{123}I-β-CIT is one of the DAT tracers most frequently used. Other ^{123}I-labeled DAT radioligands used in some imaging centers include ^{123}I-2β-carbomethoxy-3β-(4-fluorophenyl)-*N*-(1-iodoprop-1-en-3-yl)nortropane (^{123}IACFT, or ^{123}I-Altropane [Alseres Pharmaceuticals, Inc.]), ^{123}I-*N*-(3-iodopropen-2-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropane (^{123}I-IPT), and ^{123}I-labeled *N*-(3-iodoprop-(2*E*)-enyl)-2β-carboxymethoxy-3β-(4-methylphenyl)nortropane (^{123}I-PE2I). Among other SPECT radioligands, ^{99m}Tc-TRODAT-1 (^{99m}Tc-[2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2 0.1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino]ethanethiolato(3-)-*N*2,*N*2′, *S*2,*S*2′]oxo-[1*R*-(exo-exo)]) is the only available technetium-labeled radioligand and has drawn interest because of its potential for routine clinical use. However, despite the advantageous imaging properties of technetium, the target-to-background ratio is lower for ^{99m}Tc-TRODAT-1 than for other ^{123}I-labeled radioligands, and the tracer might be less suitable for the follow-up of parkinsonian patients in whom there is a higher degree of specific signal loss in the striatum.

The wider availability of PET and PET/CT systems could be an important motivation for the development of new PET radioligands for DAT. Radioligands labeled with ^{11}C and applied in human studies include ^{11}C-PE2I (*3*), 2β-carbomethoxy-3-β-(4-fluorophenyl)tropane (^{11}C-β-CFT, also referred to as ^{11}C-WIN 35,428), ^{11}C-β-CIT, and *N*-(2-fluoroethyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (^{11}C-β-CIT-FE) (*4*). Two properties of PET radioligands for DAT are desirable. The tracer should have high affinity and selectivity for DAT, yielding a high in vivo target-to-background ratio and also providing the opportunity to visualize DAT in the midbrain (Fig. 2). This property is of particular interest in Parkinson disease (PD), because the midbrain is the site at which the cell bodies of the dopamine neurons are located and the primary site of PD pathology.

The other desirable property for new PET radioligands for DAT is labeling with ^{18}F. ^{18}F-labeled radioligands can be interesting for at least 2 reasons: the lower energy of the positron provides higher intrinsic resolution, resulting in better imaging quality, and labeling with ^{18}F allows for distribution to centers without a cyclotron, resulting in widespread clinical application. Several ^{18}F-labeled DAT radioligands have been reported, but only some have been applied to humans: ^{18}F-β-CFT, ^{18}F-2β-carbomethoxy-3β-(4-chlorophenyl)-8-(2-fluoroethyl)nortropane (^{18}F-FECNT), and ^{18}F-FP-CIT. Second-generation ^{18}F-radioligands for DAT are (*E*)-*N*-(4-fluorobut-2-enyl)-2β-carbomethoxy-3β-(4′-tolyl)nortropane (LBT-999) and fluoroethyl-PE2I. The ^{11}C analog of LBT-999 has been studied in baboons and seems to be a suitable DAT radioligand for in vivo quantification (*5*). ^{18}F-fluoroethyl-PE2I has been evaluated only in preclinical studies and seems to be a

FIGURE 1. DAT SPECT with ^{123}I-FP-CIT shows normal striatal DAT availability in patient with essential tremor, whereas asymmetric DAT loss is found in patient with PD. SPECT images were acquired at Biostructure and Bioimaging Institute, Naples, Italy.

promising DAT radioligand because of its fast kinetics and favorable metabolism (6).

Factors Influencing DAT Availability

The investigation of the effect of age on DAT availability has provided consistent results indicating a 6%–8% decline of DAT per decade, using various SPECT or PET radioligands. In addition, a PET study has demonstrated that the DAT decline is paralleled by deterioration in episodic memory and executive functioning with advancing age, suggesting that DAT binding is a powerful mediator of age-related cognitive changes as well as of cognitive functioning in general (4). DAT availability appears to be influenced also by sex, being higher in women than men. These findings should be taken under consideration when one is designing in vivo imaging studies aimed at assessing group differences in DAT availability.

Antidepressants and selective serotonin reuptake inhibitors can also induce changes in DAT availability. Preclinical and clinical studies have shown that clomipramine, citalopram, and paroxetine determine an increase in DAT availability (7). One possible explanation of such an increase is that inhibition of 5-hydroxytryptamine uptake could lead to a rapid regulation of DAT molecules to more efficiently remove dopamine from the synapse. These effects on striatal DAT should be considered, because patients often are treated with various drugs—including selective serotonin reuptake inhibitors—that can affect the quantitative outcome measures of the studies.

DAT Imaging as a Diagnostic Biomarker

DAT imaging has been successfully applied to several central nervous system disorders. Table 1 summarizes the main findings of DAT availability in movement disorders and other neurodegenerative disorders. The main application has been the quantification of the dopaminergic deficit in PD. The pathology of PD consists of the loss of dopamine neurons in the substantia nigra and the reduction of dopamine projections to the striatum. Both ^{123}I-β-CIT and ^{123}I-FP-CIT SPECT have high power to discriminate PD from normal aging, particularly when DAT availability in the putamen is evaluated. Similar results, with sensitivity and specificity between 95% and 100%, have been obtained with ^{99m}Tc-TRODAT-1, suggesting that the 3 radioligands are equally sensitive in detecting the dopamine deficit at an early stage of PD.

The main clinical application of DAT imaging is the differentiation of degenerative parkinsonism from conditions not associated with dopamine deficit, such as essential tremor and drug-induced, vascular, or psychogenic parkinsonism. Two SPECT studies—one conducted in the United States (using ^{123}I-β-CIT) and one in Europe (using ^{123}I-FP-CIT)—have reported respective sensitivities of 98% and 95% and respective specificities of 83% and 94% in the differentiation of essential tremor from PD. In the clinical setting, the utility of SPECT of DAT is to prove the presence of degenerative parkinsonism in conditions having an uncertain diagnosis and warranting appropriate treatment. A multicenter study with ^{123}I-FP-CIT SPECT has shown that DAT imaging contributed to a change in diagnosis in 52% of patients and also prompted changes in clinical management in

FIGURE 2. DAT PET with ^{11}C-PE2I in healthy control. Image was acquired on ECAT EXACT HR system (Siemens). Not only striatum but also midbrain can be visualized.

TABLE 1. DAT Imaging in Parkinsonism, Related Movement Disorders, and Other Neurodegenerative Disorders

Disease	DAT availability
PD	↓↓/↓↓↓*
Atypical parkinsonism (multiple-system atrophy, progressive supranuclear palsy)	↓↓/↓↓↓*
Essential tremor	↔†
Drug-induced or psychogenic parkinsonism	↔
Vascular parkinsonism	↔
	↓
Huntington disease	↓↓
DLB	↓↓/↓↓↓*
AD	↔/↓
Frontotemporal dementia	↓
	↓↓

*Moderate to severe reduction depending on stage of disease.

†In the U.S. ^{123}I-β-CIT study, a reduction of DAT availability has been reported in 5 patients with essential tremor.

↓ = mild reduction of DAT availability; ↓↓ = moderate reduction of DAT availability; ↓↓↓ = severe reduction of DAT availability; ↔ = no change in DAT availability.

72% of patients (*8*). In PD, DAT availability has also been found to correlate with prefrontal cognitive functions, particularly in the caudate region, whereas DAT availability in the putamen is correlated mainly with motor function (*9*). DAT imaging is not reliable for the differentiation of PD from atypical parkinsonian disorders such as multiple-system atrophy and progressive supranuclear palsy, disorders in which the degree and pattern of dopamine deficit are similar to PD.

DAT dysfunction is common to disorders characterized by Lewy-body pathology, including PD dementia and DLB. In DLB, dementia usually occurs before the development of parkinsonism, and early identification of dopamine deficit is important for the management of patients. Dopamine dysfunction is not a characteristic of AD pathology, and DAT imaging is an established tool for differential diagnosis between AD and DLB. A multicenter phase III clinical trial with ^{123}I-FP-CIT SPECT in 94 patients with probable DLB, 57 patients with possible DLB, and 147 patients with non-DLB dementia reported a mean sensitivity of 77.7% for detecting clinically probable DLB, a specificity of 90.4% for excluding non-DLB dementia, and diagnostic accuracy and positive and negative predictive values of 85.7%, 82.4%, and 87.5%, respectively (*10*). The gold standard in this study, clinical diagnosis, is far from perfect and, compared with autopsy data, has shown a sensitivity not exceeding 85%. Therefore, a sensitivity of 78% is an accurate outcome for imaging studies.

DAT Imaging as a Biomarker of Dopamine Deficit in PD

The conventional understanding about dopamine deficit and PD is that parkinsonian symptoms develop when approximately 70%–80% of dopamine neurons are lost. However, PET and SPECT studies have shown that an approximately 50% loss of dopamine terminals is required for the onset of symptoms. In hemiparkinsonian patients, the striatum contralateral to the more affected side shows about a 50% DAT loss, but the "unaffected" striatum shows about a 30% DAT loss. This finding has drawn interest toward the use of DAT imaging in preclinical PD by studying either preclinical conditions or genetic mutations associated with parkinsonism. Hyposmia is a common sign that can be present years before the onset of PD. A study of a large cohort of healthy subjects has found that approximately 10% of hyposmic subjects show a DAT loss and develop parkinsonism within 2 y and that an additional 12% of hyposmic individuals show a decrease in DAT over a 2-y follow-up (*11*). These findings suggest that idiopathic hyposmia can be a preclinical sign of PD. Rapid-eye-movement sleep behavior disorder is another common condition that can precede the onset of PD, and some studies have shown that patients with idiopathic development of this disorder show an impairment of presynaptic dopaminergic function almost to the degree seen in PD patients (*12*).

Mutations in the Parkin gene are the cause of autosomal recessive early-onset PD. Heterozygous and homozygous carriers of Parkin mutations already show a dopaminergic deficit at a preclinical stage, and the severity of the dopaminergic deficit seems to be related to the number of mutated alleles. Taken together, these findings strengthen the observation that DAT imaging can be a sensitive marker for early and presymptomatic diagnosis of PD and that strategies combining dopaminergic imaging with early clinical signs or symptoms (i.e., olfactory loss or rapid-eye-movement sleep behavior disorder) and known genetic mutations for PD can be used to identify individuals at risk for PD before the onset of motor symptoms (*13*).

DAT Imaging as a Biomarker of Progression in PD

The decline of DAT as the disease progresses is an exponential process that can be followed by longitudinal DAT imaging (*14*). PET and SPECT studies have shown that the decrease in DAT is approximately 8%–10% per year; thus, the rate of decline of dopamine function is approximately 10 times faster in PD than in normal aging. The possibility of quantifying the progression of dopamine dysfunction has raised the question of whether imaging of dopamine function with DAT SPECT or 6-fluoro-L-dopa (FDOPA) PET could be used as a surrogate biomarker of disease progression to assess the effect of putative neuroprotective or disease-modifying drugs.

DAT Imaging as a Biomarker of Therapy Monitoring

DAT SPECT and FDOPA PET are imaging modalities that would satisfy the requirements for a biomarker of disease progression, because they correlate with the number of dopamine neurons and with the stage and severity of PD symptoms. Two independent clinical trials with ^{123}I-β-CIT SPECT (Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson's Disease, or CALM-PD) and ^{18}F-FDOPA PET (Requip [ropinirole; GlaxoSmithKline] as Early Therapy Versus L-Dopa-PET), or REAL-PET) have shown that PD patients treated with a D_2 agonist, either pramipexole or ropinirole, have a slower progression of dopamine deficit than do patients treated with L-dopa. However, the findings of the 2 studies have raised several questions about interpretation of the results. Are D_2 agonists neuroprotective? Is L-dopa neurotoxic? Is L-dopa interfering with DAT expression? Some of these questions remain unanswered. Preclinical and clinical studies on a small number of research subjects have shown that L-dopa or D_2 agonists have small or insignificant effects on DAT. A subsequent randomized, double-blind, placebo-controlled trial (Earlier Versus Later Levodopa Therapy in Parkinson Disease, or ELLDOPA) in 361 PD patients assigned to receive different daily doses of L-dopa (150, 300, or 600 mg) or placebo showed a significant clinical benefit of L-dopa over placebo. In the ^{123}I-β-CIT SPECT substudy of 142 patients from the same cohort, the DAT decline was more significant in the L-dopa groups than in the placebo group, with the difference being greatest in the group receiving the highest L-dopa dose. The discrepancy between the clinical effect of L-dopa and the results of the neuroimaging study questions the interpretation of ^{123}I-β-CIT SPECT in the presence of dopaminergic agents (*15*).

Although many unresolved questions remain about the usefulness of DAT imaging or FDOPA PET as surrogate biomarkers of disease progression, these imaging modalities seem to be useful molecular biomarkers to assess the effects of restorative therapies on the primary pathologic dysfunction of PD. DAT imaging and FDOPA PET have been used in preclinical models of PD using either fetal mesencephalic cells or glial cell line–derived nerve factor or in applied studies on PD patients who have received transplanted mesencephalic cells (*16*) or were treated with glial cell line–derived nerve factor, to assess the integrity of the dopaminergic system before and after treatment. DAT imaging has also been used to evaluate longitudinally the effect of deep-brain stimulation of the subthalamic nucleus on DAT availability in PD patients with advanced disease (*17*).

DAT Imaging in ADHD

DAT imaging has also been applied to the study of neuropsychiatric disorders in which the dopaminergic system is implicated. Attention-deficit hyperactivity disorder (ADHD) is a pediatric psychiatric condition characterized by the presence of inattention, hyperactivity, and impulsivity. The disorder can also manifest in adults, with a prevalence of 2%–4%. Symptoms can be alleviated by treatment with methylphenidate. Imaging studies of DAT have found somewhat contradictory results, probably related to differences in patient populations, imaging modalities, or radioligands used. Some studies on children and adults with ADHD have reported increased striatal DAT availability (*18*), whereas other studies have indicated no changes or, rather, decreased DAT availability in adults with ADHD (*19*). A PET study with ^{11}C-PE2I in adolescents with ADHD has reported a decrease in DAT availability in the midbrain, suggesting that the substantia nigra is also involved in the dopamine dysfunction associated with ADHD (*3*). More recently, Volkow et al., in studying 55 unmedicated adults with ADHD, reported decreased DAT availability in the caudate and other brain areas (such as the nucleus accumbens and the midbrain) involved in reward and motivation, suggesting a specific impairment of the dopamine reward pathway in ADHD (*20*). Although partially controversial, these studies suggest that the dopamine system is implicated in the pathophysiology of ADHD and that DAT imaging can be used to examine the functional status of the system and to monitor the effect of methylphenidate treatment.

CONCLUSION

DAT is a transmembrane protein involved in the regulation of extracellular levels of dopamine. Currently, SPECT radioligands for DAT, such as ^{123}I-FP-CIT, ^{123}I-β-CIT, and ^{99m}Tc-TRODAT-1, represent molecular imaging tools available for daily practice. The development of ^{18}F-radioligands for DAT may provide new opportunities for more widespread use of PET or PET/CT in the diagnostic work-up of patients with PD or related movement disorders.

ACKNOWLEDGMENTS

REFERENCES

1. Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. *Toxicol Appl Pharmacol.* 2005;204:355–360.
2. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using ^{123}I-labelled dopamine transporter ligands, version 2. *Eur J Nucl Med Mol Imaging.* 2009;37:443–450.
3. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. *Biol Psychiatry.* 2005;57:229–238.
4. Erixon-Lindroth N, Farde L, Wahlin TB, Sovago J, Halldin C, Backman L. The role of the striatal dopamine transporter in cognitive aging. *Psychiatry Res.* 2005;138:1–12.
5. Saba W, Valette H, Schollhorn-Peyronneau MA, et al. [^{11}C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. *Synapse.* 2007;61:17–23.
6. Varrone A, Steiger C, Schou M, et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [^{18}F]FE-PE2I, a new dopamine transporter PET radioligand. *Synapse.* 2009;63:871–880.
7. Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with ^{123}I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. *J Nucl Med.* 2007;48:359–366.
8. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using ^{123}I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. *Mov Disord.* 2004;19:1175–1182.
9. Muller U, Wachter T, Barthel H, Reuter M, von Cramon DY. Striatal [^{123}I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. *J Neural Transm.* 2000;107:303–319.
10. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with ^{123}I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *Lancet Neurol.* 2007;6:305–313.
11. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. *Ann Neurol.* 2004;56:173–181.
12. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. *Brain.* 2005;128:126–137.
13. Marek K, Jennings D. Can we image premotor Parkinson disease? *Neurology.* 2009;72(7, suppl)S21–S26.
14. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. *J Nucl Med.* 2004;45:1694–1697.
15. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? *J Neurol.* 2005;252(suppl 4):IV37–IV42.
16. Pogarell O, Koch W, Gildehaus FJ, et al. Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. *Eur J Nucl Med Mol Imaging.* 2006;33:407–411.
17. Hesse S, Strecker K, Winkler D, et al. Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up. *J Neurol.* 2008;255:1059–1066.
18. Spencer TJ, Biederman J, Madras BK, et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using Altropane. *Biol Psychiatry.* 2007;62:1059–1061.
19. Hesse S, Ballaschke O, Barthel H, Sabri O. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. *Psychiatry Res.* 2009;171:120–128.
20. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. *JAMA.* 2009;302:1084–1091.